Compare MMLP & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMLP | GANX |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.1M | 78.5M |
| IPO Year | 2002 | 2021 |
| Metric | MMLP | GANX |
|---|---|---|
| Price | $2.45 | $1.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.00 | ★ $7.50 |
| AVG Volume (30 Days) | 19.7K | ★ 792.5K |
| Earning Date | 04-22-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.78% | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,653,009,000.00 | $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 0.65 | N/A |
| 52 Week Low | $1.89 | $1.41 |
| 52 Week High | $3.54 | $4.34 |
| Indicator | MMLP | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 53.23 | 48.92 |
| Support Level | $2.22 | $1.66 |
| Resistance Level | $2.49 | $2.09 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 82.05 | 60.00 |
Martin Midstream Partners LP has a diverse set of operations focused on the United States Gulf Coast region. The company's business lines include terminalling, processing, storage, and packaging services for petroleum products and by-products, including the refining of naphthenic crude oil; land and marine transportation services for petroleum products and by-products, chemicals, and specialty products; sulfur and sulfur-based products processing, manufacturing, marketing, and distribution; and natural gas liquids marketing, distribution and transportation services. The company operates in four segment Terminalling and storage, Transportation, Sulfur service, and Specialty products segment. The majority of the revenue is derived from the Specialty products segment.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.